FBIO
Fortress Biotech Inc

8,956
Mkt Cap
$87.53M
Volume
243,690.00
52W High
$4.20
52W Low
$1.33
PE Ratio
-10.53
FBIO Fundamentals
Price
$2.82
Prev Close
$2.76
Open
$2.76
50D MA
$2.84
Beta
0.98
Avg. Volume
959,507.35
EPS (Annual)
-$2.69
P/B
1.57
Rev/Employee
$571,039.60
Loading...
Loading...
News
all
press releases
Envestnet Asset Management Inc. Sells 98,195 Shares of Fortress Biotech, Inc. $FBIO
Envestnet Asset Management Inc. lessened its holdings in Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) by 36.7% during the second quarter, according to its most recent 13F filing with the...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Upgraded at Wall Street Zen
Wall Street Zen upgraded Fortress Biotech from a "hold" rating to a "buy" rating in a report on Sunday...
MarketBeat·6d ago
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Issues Earnings Results
Fortress Biotech (NASDAQ:FBIO - Get Free Report) announced its quarterly earnings results on Friday. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the...
MarketBeat·13d ago
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Rating Lowered to Hold at Wall Street Zen
Wall Street Zen downgraded Fortress Biotech from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·13d ago
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Should You Sell...
MarketBeat·14d ago
News Placeholder
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of +125.58% and -25.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
Kamada (KMDA) Misses Q3 Earnings Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -10.00% and +1.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -11.67% and -90.26%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23d ago
News Placeholder
Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -47.15% and -4.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·25d ago

Latest FBIO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.